Cardinal Health Raises Fiscal 2027 Growth Targets for Two Segments
Cardinal Health raised its fiscal 2027 earnings forecast after Q1 non-GAAP EPS rose 28% to $3.26. Revenue increased 5% to $67.513 billion. Pharmaceutical and Specialty Solutions revenue grew 6%, while Global Medical Products and Distribution revenue was flat. The company also completed $500 million in share repurchases.
How this was made
The 30-second read
Why it matters
The guidance upgrade is a primary disclosure that can shift valuation models and trigger buying interest.
Market read
Guidance raise is a material catalyst for CAH and may influence peers in the health‑care distribution space.
What to watch
The profit decline in the Global Medical Products segment may temper enthusiasm.
Background
Cardinal Health reported Q1 results with a 28% rise in non‑GAAP diluted EPS and subsequently lifted its FY2027 outlook.
Ticker impact
Cardinal Health raised its fiscal 2027 non‑GAAP EPS outlook to $12.80‑$13.00, up from $12.40‑$12.60, after a 28% Q1 earnings beat.
likely upward pressure as investors price in higher future earnings
The company posted a 28% EPS jump and increased its EPS range, a material, fresh development for a large‑cap health distributor.
Market effects
Higher earnings guidance may lift the broader pharmaceutical distribution sector.
U.S. health‑care stocks could see modest gains.
Limited to U.S. markets; no direct global ripple.
Counterpoint
If the guidance assumes continued tariff refunds, any policy change could reverse the upside.
Key entities
- companyCardinal Health
U.S. pharmaceutical and medical product distributor (ticker CAH).
